Rejean Ruel
Merck & Co.
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Rejean Ruel.
Biochimica et Biophysica Acta | 2000
Mark Abramovitz; Mohammed Adam; Yves Boie; Marie-Claude Carrière; Danielle Denis; Claude Godbout; Sonia Lamontagne; C. Rochette; Nicole Sawyer; Nathalie Tremblay; Michel Belley; Michel Gallant; Claude Dufresne; Yves Gareau; Rejean Ruel; Helene Juteau; Marc Labelle; Nathalie Ouimet; Kathleen M. Metters
Stable cell lines that individually express the eight known human prostanoid receptors (EP(1), EP(2), EP(3), EP(4), DP, FP, IP and TP) have been established using human embryonic kidney (HEK) 293(EBNA) cells. These recombinant cell lines have been employed in radioligand binding assays to determine the equilibrium inhibitor constants of known prostanoid receptor ligands at these eight receptors. This has allowed, for the first time, an assessment of the affinity and selectivity of several novel compounds at the individual human prostanoid receptors. This information should facilitate interpretation of pharmacological studies that employ these ligands as tools to study human tissues and cell lines and should, therefore, result in a greater understanding of prostanoid receptor biology.
The EMBO Journal | 1999
Steven Xanthoudakis; Sophie Roy; Dita M. Rasper; Trevor Hennessey; Yves Aubin; Robin Cassady; Paul Tawa; Rejean Ruel; Antony Rosen; Donald W. Nicholson
The activation of caspases represents a critical step in the pathways leading to the biochemical and morphological changes that underlie apoptosis. Multiple pathways leading to caspase activation appear to exist and vary depending on the death‐inducing stimulus. We demonstrate that the activation of caspase‐3, in Jurkat cells stimulated to undergo apoptosis by a Fas‐independent pathway, is catalyzed by caspase‐6. Caspase‐6 was found to co‐purify with caspase‐3 as part of a multiprotein activation complex from extracts of camptothecin‐treated Jurkat cells. A biochemical analysis of the protein constituents of the activation complex showed that Hsp60 was also present. Furthermore, an interaction between Hsp60 and caspase‐3 could be demonstrated by co‐immunoprecipitation experiments using HeLa as well as Jurkat cell extracts. Using a reconstituted in vitro system, Hsp60 was able to substantially accelerate the maturation of procaspase‐3 by different upstream activator caspases and this effect was dependent on ATP hydrolysis. We propose that the ATP‐dependent ‘foldase’ activity of Hsp60 improves the vulnerability of pro‐caspase‐3 to proteolytic maturation by upstream caspases and that this represents an important regulatory event in apoptotic cell death.
Bioorganic & Medicinal Chemistry | 1999
Laurent Gil; Yongxin Han; Evan E. Opas; Gideon A. Rodan; Rejean Ruel; J. Gregory Seedor; Peter C. Tyler; Robert N. Young
Conjugates of bisphosphonates (potential bone resorption inhibitors) and prostaglandin E2 (a bone formation enhancer) were prepared and evaluated for their ability to bind to bone and to liberate, enzymatically, free PGE2. The conjugate 3, an amide at C-1 of PGE2 proved to be too stable in vivo while conjugate 6, a thioester, was too labile. Several PGE2, C-15 ester-linked conjugates (18, 23, 24 and 31) were prepared and conjugate 23 was found to bind effectively to bone in vitro and in vivo and to liberate PGE2 at an acceptable rate. A 4-week study in a rat model of osteoporosis showed that 23 was better tolerated and more effective as a bone growth stimulant than daily maximum tolerated doses of free PGE2.
Bioorganic & Medicinal Chemistry Letters | 2002
Michel Gallant; Marie-Claude Carrière; Anne Chateauneuf; Danielle Denis; Yves Gareau; Claude Godbout; Gillian Greig; Helene Juteau; Nicolas Lachance; Patrick Lacombe; Sonia Lamontagne; Kathleen M. Metters; C. Rochette; Rejean Ruel; Deborah Slipetz; Nicole Sawyer; Nathalie Tremblay; Marc Labelle
Potent and selective ligands for the human EP3 prostanoid receptor are described. Biaryl compounds bearing a tethered ortho substituted acidic moiety were identified as potent EP3 antagonists based on the SAR described herein. The binding affinity of key compounds on all eight human prostanoid receptors is reported.
Bioorganic & Medicinal Chemistry Letters | 1999
Rejean Ruel; Patrick Lacombe; Mark Abramovitz; Claude Godbout; Sonia Lamontagne; C. Rochette; Nicole Sawyer; Rino Stocco; Nathalie Tremblay; Kathleen M. Metters; Marc Labelle
A new class of potent and selective ligands for the human EP1 prostanoid receptor is described. SAR studies reported herein allowed the identification of several potent dibenzazocinones bearing an acylsulfonamide side chain. The binding affinity of these compounds on all eight human prostanoid receptors is reported.
Tetrahedron Letters | 1998
Patrick Lacombe; Bastien Castagner; Yves Gareau; Rejean Ruel
Abstract The reduction of solid supported olefinic substrate using diimide is described. The diimide, prepared from sulfonylhydrazide, was found to efficiently reduce the olefinic substrates. Typically, the reaction proceeds in over 90% yield to afford the reduction product cleanly after cleavage from the Wang resin.
Tetrahedron Letters | 1996
Élise Balaux; Rejean Ruel
Abstract Primary and secondary α-haloesters are converted to succinic diesters in good yield by treatment with SmI 2 -HMPA.
Journal of Biological Chemistry | 1998
Margarita Garcia-Calvo; Erin P. Peterson; Barbara Leiting; Rejean Ruel; Donald W. Nicholson; Nancy A. Thornberry
Archive | 2000
Patrick Lacombe; Marc Labelle; Rejean Ruel
Journal of Organic Chemistry | 1995
Rejean Ruel; Jean-Pierre Bouvier; Robert N. Young